A previously unrecognized action as a potent inhibitor of the dominant mutation that confers drug resistance to all well-tolerated treatments in patients with certain leukemia types has been found in Axitinib.
Study identifies reasons for ibrutinib discontinuation in patients with chronic lymphocytic leukemiaFebruary 27, 2015
About 10% of patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib discontinued their therapy due to disease progression during clinical studies.
A subset of antiviral immune cells could prevent CMV infections in bone marrow transplant recipientsFebruary 24, 2015
A small subset of antiviral immune cells may be enough to fight and even prevent the disease caused by cytomegalovirus (CMV) in patients that receive bone marrow transplants.
Young adult survivors of leukemia and lymphoma are more likely to report high stress compared with older survivors of the same diseases.
The ASCO has announced that the transformation of treatment for chronic lymphocytic leukemia (CLL) is its Cancer Advance of the Year.
A new test may reveal which patients will respond to treatment for graft-versus-host disease (GVHD), a serious complication that can arise from stem cell SCT.
According to results of a new, retrospective study, the risk of developing leukemia after radiation therapy or chemotherapy for early stage breast cancer is double that previously reported.
An oral targeted agent has shown encouraging activity and limited side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML), according to research.
Patients with advanced leukemia, when treated with a new type of cancer therapy that blocks mutated IDH2 protein, showed dramatic results in a clinical trial.
Pediatric patients with acute lymphoblastic leukemia (ALL) showed a 90% response rate from the first trials testing an investigational personalized cellular therapy known as CTL019.
Among early-stage breast cancer patients who undergo chemotherapy and/or radiation treatment, the risk for developing treatment-related leukemia, though low, is still double what experts had previously thought.
The drug, which spurs the body's immune system, has now been approved to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (ALL).
For pediatric patients with acute lymphoblastic leukemia (ALL), obesity increases risk of persistent diseaseOctober 28, 2014
Obese pediatric patients with acute lymphoblastic leukemia (ALL) are more likely to have minimal residual disease.
For younger patients with an acute lymphoblastic leukemia (ALL) subtype, modifying treatment based on chemotherapy response can make a vital difference.
Results of a phase I clinical trial showed that a new drug targeting mitochondrial function in human cancer cells was safe and showed some efficacy in a heavily pretreated cohort of patients.
Tyrosine kinase inhibitors (TKIs) may be effective for the treatment of acute lymphoblastic leukemia (ALL).
Many young adults with the most common form of acute lymphoblastic leukemia (ALL) have a high-risk subtype with a poor prognosis and could benefit from drugs used to treat other types of leukemia.
Weekend hospital admission for pediatric patients with newly diagnosed leukemia is associated with a longer length of stay, slightly longer wait to start chemotherapy, and higher risk for respiratory failure.
CPI-613 safe and somewhat efficacious for the treatment of patients with relapsed or refractory leukemia.
A select team of immune-system cells from patients with leukemia can be multiplied in the laboratory, creating a horde of natural killer cells that can be used to target and destroy the cancer cells.
By analyzing the DNA sequence of patients at different stages of leukemia, researchers have discovered mutations in genes that lead to childhood leukemia of the acute lymphoblastic type, the most common childhood cancer.
Weekend admission for pediatric patients with leukemia associated with a longer length of stay.
The EUROCARE study, the largest population-based study of survival in European blood cancer patients to date, analyzed data from 30 cancer registries, involving all patients with cancer diagnoses in 20 European countries.
Scientists have developed a test which accurately predicts the prognosis for patients with the most common form of leukemia.
An experimental immunotherapy agent was placed on the US Food and Drug Administration's fast track to market approval after overwhelmingly positive results were seen in patients with leukemia. In early trials, 89% of patients who received the personalized immunotherapy known as CTL019 saw their cancers disappear.
Scientists have discovered that a gene previously linked to leukaemia could provide an urgently needed target for the development of drugs to treat patients with 'triple negative' breast cancer.
Cancer cells decide whether to live or die after a short period of intense exposure to targeted therapy, opposing the current requirement for continuous treatment, according to a new study.
Researchers in Melbourne, Australia, have shown that switching off a gene called Pax5 could cause a type of leukemia, and restoring its function could cure the disease.
Children in remission from acute lymphocytic leukemia (ALL) must take 6-mercaptopurine (6MP) for 2 years to prevent disease reemergence; however, a study shows that an estimated 25% of children in remission are not taking this essential maintenance medication at least 90% of the time, tripling their relapse risk.
- Two major studies strengthen case for prostate cancer drug before chemotherapy
- Single therapy offers improved survival in younger patients with limited brain metastases
- Use of adjuvant systemic therapy increasing for gastrointestinal stromal tumors (GIST)
- People who drink 3-5 cups of coffee per day less likely to develop clogged arteries
- Statin hyporesponders may have blocked arteries
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|